# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The positive opinion is based on results from two pivotal Phase 3 trials, INSPIRE and COMMAND, that evaluated the efficacy an...
New safety and efficacy data in heavily pre-treated patients with metastatic colorectal cancer (CRC), from a Phase 1 study of A...
Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnose...
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled ...
Cantor Fitzgerald initiates coverage on AbbVie with an Overweight rating and a $200 price target. AbbVie is set to manage Humir...